Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bromocriptine for "negative" schizophrenia.

S Levi-Minzi1, P C Bermanzohn, S G Siris

  • 1Robert Wood Johnson School of Medicine, New Brunswick, NJ.

Comprehensive Psychiatry
|May 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical issues related to depression in schizophrenia: an international survey of psychiatrists.

Acta psychiatrica Scandinavica·2002
Same author

Suicide and schizophrenia.

Journal of psychopharmacology (Oxford, England)·2001
Same author

Depression in schizophrenia: recognition and management in the USA.

Schizophrenia research·2001
Same author

Hierarchical diagnosis in chronic schizophrenia: a clinical study of co-occurring syndromes.

Schizophrenia bulletin·2000
Same author

Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents.

The American journal of psychiatry·2000
Same author

Relationship of panic attacks to paranoia.

The American journal of psychiatry·1999

Dopamine agonists like bromocriptine may help schizophrenia negative symptoms when used with neuroleptics. This study found bromocriptine improved symptoms in patients unresponsive to other treatments, with few side effects.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia's negative symptoms may stem from reduced central dopaminergic activity.
  • Dopamine agonists are explored for treating these symptoms, but caution is needed due to psychosis risks.

Observation:

  • Six patients with chronic schizophrenia and negative symptoms, on neuroleptic medication, received adjunctive bromocriptine (10-20 mg/d).
  • Five patients had not responded to anticholinergic antiparkinsonian drugs, suggesting bromocriptine's effect wasn't solely counteracting akinesia.
  • This represents a novel trial of bromocriptine in this specific patient group.

Findings:

  • Adjunctive bromocriptine showed favorable responses in patients with chronic negative symptoms of schizophrenia.
  • Long-term follow-up (27 patient-years) indicated sustained benefits and minimal psychotic exacerbation.

Related Experiment Videos

  • Bromocriptine's efficacy appeared independent of its potential to counteract neuroleptic-induced akinesia.

    • Implications:

    • Dopamine agonist therapy, specifically bromocriptine, warrants further investigation as an adjunct for negative symptoms in schizophrenia.
    • These findings suggest a potential therapeutic avenue for treatment-resistant negative symptoms.
    • Further research is needed to confirm these preliminary observations and optimize treatment strategies.